Qiagen (QGEN) Offering Possible 5.26% Return Over the Next 15 Calendar Days

This article was originally published on this site

Qiagen’s most recent trend suggests a bullish bias. One trading opportunity on Qiagen is a Bull Put Spread using a strike $42.00 short put and a strike $37.00 long put offers a potential 5.26% return on risk over the next 15 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $42.00 by expiration. The full premium credit of $0.25 would be kept by the premium seller. The risk of $4.75 would be incurred if the stock dropped below the $37.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Qiagen is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Qiagen is bullish.

The RSI indicator is above 80 which suggests that the stock is in overbought territory.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Qiagen

QIAGEN and DiaSorin Get FDA Approval for LIAISON QFT-Plus
Thu, 28 Nov 2019 13:15:01 +0000
QIAGEN (QGEN) and DiaSorin begin the commercial launch of the QFT-Plus test in the United States, following the FDA clearance.

The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen
Wed, 27 Nov 2019 12:26:05 +0000
Here’s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 26) Allakos Inc (NASDAQ: ALLK ) Alnylam Pharmaceuticals, …

QIAGEN and DiaSorin Receive FDA Approval for The LIAISON QuantiFERON-TB Gold Plus Test on LIAISON Platforms and Begin Commercial Launch
Wed, 27 Nov 2019 07:00:00 +0000
QIAGEN and DiaSorin receive FDA approval for the LIAISON QuantiFERON-TB Gold Plus Test on LIAISON platforms and begin commercial launch

ROSEN, A GLOBAL LAW FIRM, Continues to Investigate Securities Claims Against QIAGEN N.V. – QGEN
Mon, 25 Nov 2019 22:02:20 +0000
NEW YORK, Nov. 25, 2019 — Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Qiagen N.V..

QIAGEN Expands Existing Deal With LabCorp for Better Treatment
Thu, 21 Nov 2019 13:42:01 +0000
QIAGEN (QGEN) announces the expansion of partnership with LabCorp (LH) to make genetic information available for clinical and research purposes.

Be Sociable, Share!

Related Posts